Loading clinical trials...

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis | Clinical Trials | Clareo Health

RECRUITING

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

NCT06207812•M.D. Anderson Cancer Center

View on ClinicalTrials.gov

Summary

To follow up with all our participants with juvenile-onset mycosis fungoides, check on their status, and ask them or their parents about long term outcomes associated with their condition.

Detailed Description

Primary Objective -To characterize the long-term outcomes associated with juvenile-onset mycosis fungoides (jMF) and lymphomatoid papulosis (lyp). The study will consider metrics such as 5-year and 10-year overall survival, and overall disease activity. Secondary objective -To characterize treatments and associated comorbidities.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•To be eligible, participants had to be diagnosed with jMF or lyp before age 20. In the case of participants below the age of 18, parents and not the children will be contacted for participation (children are exempt from participation as their parents may answer our study questions).

Exclusion Criteria

•Participants older than 20 years of age at diagnosis

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

January 19, 2024

Primary Completion Date

January 12, 2028

Completion Date

January 12, 2028

Last Updated

January 26, 2026

Enrollment

100

ESTIMATED participants

Conditions

Lymphomatoid PapulosisMycosis Fungoides

Contacts

Julia Dai, MD

CONTACT

(713) 515-7961 jdai6@mdanderson.org

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868

Cutaneous T Cell LymphomaCutaneous T-Cell Lymphoma/Mycosis Fungoides+1 more

View study

RECRUITINGPHASE3

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

NCT06470451

CTCL/ Mycosis FungoidesCTCL+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

Inclusion Criteria

Exclusion Criteria

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Photopheresis in Early-stage Mycosis Fungoides

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome